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Objective: To determine the requirements for successful implementation of the PKGTM into clinical 
management of Parkinson’s, through a multi- center service evaluation. 
 
Background: PKGTM objective measurements could play a significant role in better understanding of 
the fluctuating nature of Parkinson’s. This could add to the information presented at specialist reviews 
to support decision-making. 
 
Methods: In collaboration with UK Parkinson’s Excellence Network and GKC, UK specialist 
Parkinson’s services were asked to apply the technology whenever they felt it could bring value. 
 
Results: To date, 214 datasheets were collected from seven services.  The initially intended and the 
resultant clinical decision were collected  for 171 patients. For 47% the resultant decision differed. Of 
the 171, advanced therapy was considered for 29.2% prior to measurement. For 26% this was 
afterwards no longer considered the next step. Similarly, advanced therapy was decided for 29.8% 
after measurement. For 27.5% of these this was initially not considered. 155 patients reported their 
experience: 78% reported a ‘positive experience’, 20% reported a ‘neutral experience’ and 2% a 
‘negative experience’. Patients generally felt results were confirmative of known symptoms, but 
improving discussion and enhancing confidence in therapy. For 214 patients, clinicians reported the 
scenario, had PKG not been available. This highlighted a range of interventions that may become 
redundant, such as patient diaries (16.8%), referrals (14.5%), earlier follow-up (13.6%), home visits 
(2.3%). Clinician feedback noted the need for practical issues to be managed such as training, 
interpretation support, receiving reports in timely manner and being able to share with colleagues and 
patients. 
 
Conclusion: A difference in clinical decision-making for symptom control and change in the actions 
taken within the wider care plan was demonstrated. The device was readily accepted by patients 
as a valuable tool, and supported a collaborative relationship with their clinicians. Practical issues to 
be considered were also demonstrated. 
 
